rheumatoid arthritis dmard vs biologic Updated American College of Rheumatology recommendations suggest using first-line DMARDs in combination with biologic agents and nonbiologic DMARDs to achieve ...

Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

The modern approach to managing rheumatoid arthritis consists of employing sensitive outcome assessment tools such as the health assessment questionnaire (HAQ), the disease activity scale (DAS), or ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Before the JAK inhibitors came out, we had ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA who responded to DMARD therapy showed reduced microbiome levels of certain bacteria. DMARD ...

In recent years, biologic disease-modifying antirheumatic drugs (DMARDs) have advanced the treatment of rheumatoid arthritis (RA). However, poor adherence to treatments have increased the patient and ...

DMARDS can increase the chances of remission in patients with rheumatoid arthritis, even after DMARD usage is stopped, according to a Swedish study. Share on Pinterest Early treatment with ...

Using a combination of three traditional disease-modifying antirheumatic drugs for treating recent-onset rheumatoid arthritis is not only more cost-effective, but results in better long-term worker ...

For many years, RA was treated primarily with nonsteroidal anti-inflammatory drugs (NSAIDs). While NSAIDS, including the newer generation cyclo-oxygenase (COX-2) inhibitors, decrease inflammation and ...

In past decades, remission was seldom assessed as an outcome measure... An earlier randomized, placebo-controlled study of stoppage versus continuation of DMARD therapy in patients with longstanding ...

Only slightly more than half of patients with newly diagnosed rheumatoid arthritis initiated therapy within 1 year. Objectives: To determine the rate of timely disease-modifying antirheumatic drug ...

Although low-dose glucocorticoids, in conjunction with DMARDs, are known to halt or severely retard the erosive destruction of joints in patients with early rheumatoid arthritis (RA), the potential ...